The term "acute coronary syndrome" encompasses a range of thrombotic coronary artery diseases, including unstable angina and both ST-segment elevation and non-ST-segment elevation myocardial infarction.
Raymond Gibbons, MD (Mayo Clinic, Pres/American Heart Association), said COURAGE trial findings suggest that "hundreds of thousands of Americans with stable angina who received coronary stents did not need them."
Coronary collateral circulation is associated with preserved myocardial contractility; preexisting collaterals may be more important than neoangiogenesis for angina & MI patients.
Cardiothoracic Surgery Notes, an online interactive review developed by residents in cardiothoracic surgery. CTSN provides a resource for fundamental essential facts for board review and sources for additional information.
Martin B. Leon, MD, violated academic ethics of the highest order by leaking results of the COURAGE trial prematurely, denigrating its design, discrediting its results, to protect pocketbooks of interventional cardiologists and stent industry. Sanctions
ß-Blockers exert antiatherosclerotic effects by reducing affinity of LDL-C to vessel wall proteoglycans & blunting of catecholamine-induced increases in endothelial permeability to lipoproteins...
Statins have pleiotropic effects: anti-inflammatory, immunomodulatory, antithrombotic, and vascular activity, & may improve left ventricular myocardial function & left ventricular diastolic function by increasing vascular elasticity.
A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
Results from the first U.S. clinical trial investigating the benefit of using a patient's own (autologous) selected adult stem cells, called CD34+ cells, to treat coronary artery disease are promising.
A major limitation of percutaneous therapy (PCI) for the treatment of chronic total occlusions (CTOs) is the inability to cross with a wire. We report successful recanalization of a CTO using Intraluminal Wire (tm)...
Major limitation of percutaneous therapy (PCI) for the treatment of chronic total occlusions (CTOs) is the inability to cross with a wire. Recanalization with Intraluminal Wire, combines guidance of wire tip and radiofrequency ablation.
Every 3rd coronary angiography patient presents 1+ total arterial occlusion. Guidewire failure often precludes subsequent repair of the lesion in the cardiac cath lab; many of these patients are ultimately managed surgically or medically.
Techniques for penetrating chronic total occlusion (CTO) to ensure complete revascularization using percutaneous coronary techniques. Success is only 50–75%, even in the best hands. How to improve?
=Asahi Tornus, specialty catheter by Abbott Vascular Devices =Used for crossing chronic total occlusions (CTOs) =Used with Asahi Confianza or Asahi Miracle Bros guidewires
Articles on the various questions, problems, and controversies currently plaguing drug-eluting stents: deployment techniques, stent qualities, antiplatelet therapies, and etiologies of post-DES thrombosis and restenosis.
We must optimize stent deployment & maintain a registry of how well (or poorly) we use drug-eluting stents. Instead of asking “Which stent?” or “How much anti-platelet therapy?” we must ask “How effectively are we deploying our stents?”
Medical dictionary, ICD-9 codes, pharmaceutical companies, medical abbreviations, hospitals and associations. Plus medical news and other searches for the medical, pharmaceutical or healthcare professional.
Hormone-suppressing treatments for aggressive prostate cancer may cause heart attacks to occur 2.5 years earlier in men with risk factors for heart disease.
Welcome to AskDrWiki.com where you can publish your review articles, clinical notes, pearls, and medical images on the site. Using a wiki anyone with a medical background can contribute or edit medical articles. The Main focus has been on Cardiology and E
B. George, S. Seals, and I. Aban. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 21 (4):
686-94(August 2014)Anàlisi de supervivència; Introductori; SAS.
S. Deb, P. Austin, J. Tu, D. Ko, C. Mazer, A. Kiss, and S. Fremes. The Canadian journal of cardiology, 32 (2):
259-65(February 2016)Propensity score; CV; Introductori<br/><br/>Taula 1 de ATE/ATT per mètode.
S. Pocock, T. Clayton, and G. Stone. Journal of the American College of Cardiology, 66 (25):
2886-98(December 2015)Disseny; Dissenys adaptatius; Tests d'equivalència; Early stopping; RCT; Introductori; CV<br/><br/>Molts exemples i bons gràfics.
S. Pocock, J. McMurray, and T. Collier. Journal of the American College of Cardiology, 66 (23):
2648-62(December 2015)Disseny; RCT; CV; Introductori; Comparacions múltiples; Composite endpoints; Intention to treat; Anàlisi de subgrups.